<DOC>
	<DOCNO>NCT02610582</DOCNO>
	<brief_summary>The purpose study proof safety efficacy single subretinal injection rAAV.hCNGA3 patient CNGA3-linked achromatopsia .</brief_summary>
	<brief_title>Safety Efficacy Single Subretinal Injection rAAV.hCNGA3 Patients With CNGA3-linked Achromatopsia</brief_title>
	<detailed_description>Title : Safety efficacy single subretinal injection rAAV.hCNGA3 patient CNGA3-linked achromatopsia investigate exploratory , dose-escalation trial Phase : I/II Indication : CNGA3-linked achromatopsia Aim : To proof safety efficacy rAAV.hCNGA3 patient achromatopsia Study design : open , mono-center trial fellow-eye comparison Study Population : Inclusion Criteria ( Study Eye ) - clinical diagnosis achromatopsia - ≥ 18 year age - confirm mutation CNGA3 - BCVA ≥ 20/400 - minimal outer nuclear layer thickness 10µm 3° eccentricity study eye ( normal = 38±6µm ) - ability understand willingness consent study protocol - infection Human Immunodeficiency Virus ( HIV ) - negative pregnancy test woman childbearing potential ( woman two year post-menopausal surgically sterile consider childbearing potential ) Exclusion Criteria - additional interfering eye condition ( e.g . uveitis , advanced cataract ) study eye - systemic condition ( e.g . coronary heart disease , autoimmune disorder ) may affect study participation outcome measure - current recent participation study/or administration biologic agent within last three month - recent ( 6 month ) ocular surgery , intravitreal subretinal implantation medical device - know sensitivity compound use study - contraindication systemic immunosuppression - subject/partner childbearing potential unwilling use adequate contraception four month - nursing pregnant woman - cause , investigator 's opinion , render potential subject suitable study - mutation another achromatopsia gene - contraindication view plan surgery ( e.g . anaemia Hb &lt; 8g/dl , severe coagulopathy , severe blood pressure fluctuation ) - ocular opacity mature cataract - history ocular malignancy - disorder internal retina ( e.g . retinal detachment patient history ) - glaucoma define damage optic nerve - vascular retinal occlusion - diabetic patient suffer retinopathy and/or macula edema - patient treated oral corticoid within 14 day prior inclusion - systemic illness medically significant abnormal laboratory value blood analysis include renal hepatic function inclusion - absence vision contralateral eye Patient Number : Nine patient assign three cohort three patient respectively . Treatment : Each cohort receive different , increase dosage viral vector genome particle . Three cohort patient plan low , medium high dose administration level 1x10e11 rAAV8 incorporate therapeutic expression cassette . After standard three-port 23G par plana vitrectomy , balance salt solution use induce localized primary retinal detachment control fashion . Vector solution apply use disposable 41G extendible subretinal injection needle within standard 23G body fit port system . Administration unilateral ( bad eye ) patient . Primary Endpoint : Safety primary endpoint assess clinical examination ocular inflammation ( slit lamp , fundus biomicroscopy , angiography , perimetry electrophysiology ) . Systemic safety assess vital sign , routine clinical chemistry test ( include C reactive proteine , ESR ) full/differential blood count . Immunopathology essay include specific enzyme-linked immunosorbent assay humoral antibody rAAV8 capsid protein and/or CNGA3 gene product specific enzyme-linked immunosorbent spot assay monitor cellular immune reactivity rAAV8 capsid protein and/or CNGA3 gene product . Biodistribution monitor polymerase chain reaction study rAAV8 genome blood , urine , saliva lachrymal fluid . Statistical Methods : Adverse Events Serious Adverse Events document use line listing tabulation ( MetraCad code apply ) . Descriptive analysis include line chart individual patient . Standard error mean also display use line chart . This do raw measurement difference treat untreated control eye within patient . Descriptive parameter give full cohort ( n=9 ) sub-cohorts ( n=3 ) . Additionally correlation analysis perform purely descriptive manner comparison subjective objective measurement . For subject measurement , delta value interventional eye minus mean control eye value time determine . In scatter plot pair variable ( measurement pool subject ) association delta display . Time Schedule : Start trial November 2015 , end recruitment November 2016 , end trial November 2017 , duration trial per patient : one year four year follow-up .</detailed_description>
	<mesh_term>Color Vision Defects</mesh_term>
	<criteria>clinical diagnosis achromatopsia ≥ 18 year age confirm mutation CNGA3 BCVA ≥ 20/400 minimal outer nuclear layer thickness 10µm 3° eccentricity study eye ( normal = 38±6µm ) ability understand willingness consent study protocol infection Human Immunodeficiency Virus ( HIV ) negative pregnancy test woman childbearing potential ( woman two year postmenopausal surgically sterile consider childbearing potential ) additional interfere eye condition ( e.g . uveitis , advanced cataract ) study eye systemic condition ( e.g . coronary heart disease , autoimmune disorder ) may affect study participation outcome measure current recent participation study/or administration biologic agent within last three month recent ( 6 month ) ocular surgery , intravitreal subretinal implantation medical device know sensitivity compound use study contraindication systemic immunosuppression subject/partner childbearing potential unwilling use adequate contraception four month nurse pregnant woman cause , investigator 's opinion , render potential subject suitable study mutation another achromatopsia gene contraindication view plan surgery ( e.g . anaemia Hb &lt; 8g/dl , severe coagulopathy , severe blood pressure fluctuation ) ocular opacity mature cataract history ocular malignancy disorder internal retina ( e.g . retinal detachment patient history ) glaucoma define damage optic nerve vascular retinal occlusion diabetic patient suffer retinopathy and/or macula edema patient treat oral corticoid within 14 day prior inclusion systemic illness medically significant abnormal laboratory value blood analysis include renal hepatic function inclusion absence vision contralateral eye</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>CNGA3-linked</keyword>
</DOC>